ASP4000, a slow-binding dipeptidyl peptidase 4 inhibitor, has antihyperglycemic activity of long duration in Zucker fatty rats |
| |
Authors: | Keiko Tanaka-Amino Kazumi Matsumoto Yoshifumi Hatakeyama Shoji Takakura Seitaro Mutoh |
| |
Institution: | (1) Drug Discovery Research, Astellas Pharma Inc., Osaka, Tsukuba, Japan;(2) Present address: Astellas Research Technologies Co., Ltd, Osaka, Japan;(3) Development, Astellas Pharma Inc., Tokyo, Japan;(4) Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc., 5-2-3 Tokodai, Tsukuba, Ibaraki, Japan |
| |
Abstract: | ASP4000 ((2S)-1-{(1R,3S,4S,6R)-6-hydroxy-2-azabicyclo2.2.1]hept-3-yl]carbonyl}-2-pyrrolidinecarbonitrile hydrochloride) is a novel, potent and selective
dipeptidyl peptidase 4 (DPP IV, EC 3.4.14.5) inhibitor (Keiko Tanaka-Amino et al. in Eur J pharmacol 59:444–449, 2008). The
aim of the present study was to characterize the kinetic profile of and identify the long duration effect of the antihyperglycemic
activity of ASP4000. ASP4000 was found to inhibit human recombinant DPP4 activity with a K
i of 1.05 nM, a k
on value of 22.3 × 105 M−1 s−1, and a k
off of 2.35 × 10−3 M−1 s−1, with higher affinity than that of vildagliptin. The kinetic studies indicate that both the formation and dissociation of
ASP4000/DPP4 complex were faster than those of vildagliptin, and that ASP4000 slow-bindingly inhibits DPP4 with a different
mode of inhibition than vildagliptin. In addition, ASP4000 augmented the insulin response and ameliorated the glucose excursion
during the oral glucose tolerance test in Zucker fatty rats at 4 h post dosing. ASP4000 is expected to be a promising, long
duration DPP4 inhibitor for type 2 diabetes. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|